Axsome Therapeutics, Inc.
AXSM
Classificação em ações
#2377
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to... Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Preço da ação
$157.42
Valor de mercado
$8.25B
Variação (1 dia)
-1.35%
Variação (1 ano)
19.81%
País
US
Negociar Axsome Therapeutics, Inc. (AXSM)
Categoria
Healthcare
Receita da Axsome Therapeutics, Inc. (AXSM)
Receita em Jun 2026 TTM: $776.57M
De acordo com os últimos relatórios financeiros da Axsome Therapeutics, Inc., a receita atual da empresa (TTM) é $776.57M. Em 2023, a empresa obteve uma receita de $270.60M um aumento em relação a a receita do ano 2022, que foi de $50.04M. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Axsome Therapeutics, Inc. de 2013 a 2026
Receita no final de cada ano
| Ano | Receita | Alterar |
|---|---|---|
| 2026 (TTM) | $776.57M | 101.34% |
| 2024 | $385.69M | 42.53% |
| 2023 | $270.60M | 440.80% |
| 2022 | $50.04M | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
Receita de empresas similares ou concorrentes
| Empresa | Receita | Diferença de Receita | País |
|---|---|---|---|
| $12.62B | 1,525.65% |
US
|
|
| $2.23B | 186.90% |
US
|
|
| $15.74B | 1,927.42% |
AU
|
|
| $6.02B | 675.37% |
NL
|
|
| - | - |
CH
|
